Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Claudin-14 (CLDN14) is an integral membrane protein and a key component of tight junctions in epithelial and endothelial cells[1][2][4]. Tight junctions form a seal between adjacent cells and restrict the free passage of solutes and water through the paracellular space. Claudin-14 is especially important in the kidney, where it regulates calcium reabsorption by controlling the permeability of the thick ascending limb of the loop of Henle[2][3]. It physically interacts with other claudins (notably CLDN16 and CLDN19), modulating cation selectivity and transport[3]. In the inner ear, CLDN14 maintains proper ion gradients critical for hearing; loss-of-function mutations cause a form of autosomal recessive nonsyndromic sensorineural deafness (DFNB29)[1][2][4]. Genetic variants in the CLDN14 gene are strongly associated with kidney stone formation and altered bone mineral density[2][3][4]. There is emerging evidence that dysregulation of CLDN14 may contribute to tumor angiogenesis and other pathologies, but its role as a direct drug target remains under investigation[1][2]. No drugs are currently known to directly target CLDN14.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Claudin-14 (CLDN14).